IRF4 as an Oncogenic Master Transcription Factor

被引:24
|
作者
Wong, Regina Wan Ju [1 ]
Ong, Jolynn Zu Lin [1 ]
Theardy, Madelaine Skolastika [1 ]
Sanda, Takaomi [1 ,2 ]
机构
[1] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117599, Singapore
[2] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117599, Singapore
基金
英国医学研究理事会; 新加坡国家研究基金会;
关键词
IRF4; oncogene; transcription factor; mature lymphoid neoplasms; NF-KAPPA-B; GERMINAL CENTER B; INTERFERON REGULATORY FACTOR-4; MUM1/IRF4 PROTEIN EXPRESSION; STIMULATED RESPONSE ELEMENT; SEQUENCE BINDING-PROTEIN; CELL LYMPHOMA; FACTOR FAMILY; MATURE B; DIFFERENTIAL EXPRESSION;
D O I
10.3390/cancers14174314
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Master transcription factors regulate essential developmental processes and cellular maintenance that characterize cell identity. Many of them also serve as oncogenes when aberrantly expressed or activated. IRF4 is one of prime examples of oncogenic master transcription factors that has been implicated in various mature lymphoid neoplasms. IRF4 forms unique regulatory circuits and induces oncogenic transcription programs through the interactions with upstream pathways and binding partners. IRF4 is a transcription factor in the interferon regulatory factor (IRF) family. Since the discovery of this gene, various research fields including immunology and oncology have highlighted the unique characteristics and the importance of IRF4 in several biological processes that distinguish it from other IRF family members. In normal lymphocyte development and immunity, IRF4 mediates critical immune responses via interactions with upstream signaling pathways, such as the T-cell receptor and B-cell receptor pathways, as well as their binding partners, which are uniquely expressed in each cell type. On the other hand, IRF4 acts as an oncogene in various mature lymphoid neoplasms when abnormally expressed. IRF4 induces several oncogenes, such as MYC, as well as genes that characterize each cell type by utilizing its ability as a master regulator of immunity. IRF4 and its upstream factor NF-kappa B form a transcriptional regulatory circuit, including feedback and feedforward loops, to maintain the oncogenic transcriptional program in malignant lymphoid cells. In this review article, we provide an overview of the molecular functions of IRF4 in mature lymphoid neoplasms and highlight its upstream and downstream pathways, as well as the regulatory circuits mediated by IRF4.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Regulation of bifurcating B cell trajectories by mutual antagonism between transcription factors IRF4 and IRF8
    Xu, Heping
    Chaudhri, Virendra K.
    Wu, Zhiguo
    Biiouris, Konstantinos
    Dienger-Stambaugh, Krista
    Rochman, Yrina
    Singh, Harinder
    NATURE IMMUNOLOGY, 2015, 16 (12) : 1274 - 1281
  • [42] Reciprocal regulation of the Il9 locus by counteracting activities of transcription factors IRF1 and IRF4
    Carrascosa, Lucia Campos
    Klein, Matthias
    Kitagawa, Yohko
    Luckel, Christina
    Marini, Federico
    Koenig, Anika
    Guralnik, Anna
    Raifer, Hartmann
    Hagner-Benes, Stefanie
    Radler, Diana
    Bock, Andreas
    Kang, Cholho
    Lohoff, Michael
    Garn, Holger
    Schaub, Bianca
    Berberich-Siebelt, Friederike
    Sakaguchi, Shimon
    Bopp, Tobias
    Huber, Magdalena
    NATURE COMMUNICATIONS, 2017, 8
  • [43] The BTB-ZF transcription factor Zbtb20 is driven by Irf4 to promote plasma cell differentiation and longevity
    Chevrier, Stephane
    Emslie, Dianne
    Shi, Wei
    Kratina, Tobias
    Wellard, Cameron
    Karnowski, Alexander
    Erikci, Erdem
    Smyth, Gordon K.
    Chowdhury, Kamal
    Tarlinton, David
    Corcoran, Lynn M.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 211 (05): : 827 - 840
  • [44] Correction: Corrigendum: The transcription factor IRF4 is essential for TCR affinity–mediated metabolic programming and clonal expansion of T cells
    Kevin Man
    Maria Miasari
    Wei Shi
    Annie Xin
    Darren C Henstridge
    Simon Preston
    Marc Pellegrini
    Gabrielle T Belz
    Gordon K Smyth
    Mark A Febbraio
    Stephen L Nutt
    Axel Kallies
    Nature Immunology, 2014, 15 : 894 - 894
  • [45] Expression pattern analysis of IRF4 and its related genes revealed the functional differentiation of IRF4 paralogues in teleost
    Ai, Kete
    Luo, Kai
    Li, Youshen
    Hu, Wei
    Gao, Weihua
    Fang, Liu
    Tian, Guangming
    Ruan, Guoliang
    Xu, Qiaoqing
    FISH & SHELLFISH IMMUNOLOGY, 2017, 60 : 59 - 64
  • [46] A heterozygote point mutation in the transcription factor IRF4 protects from developing ascending paralysis in a Multiple Sclerosis mouse model
    Buckland, R.
    Pettitt, J.
    Sridharan, S.
    Roberts, N.
    Enders, A.
    Brustle, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (4_SUPPL) : 37 - 37
  • [47] p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma
    McKeown, Michael R.
    Giorgetti, Giulia
    Lenoir, Walter F.
    Kobylarz, Marek J.
    Hopkins, Tamara D.
    Glore, Wayne L.
    Shum, Michelle G.
    Calderon, Yare
    Mori, Kameron R.
    Gao, Hua
    Carvajal, Luis A.
    Obholzer, Nikolaus D.
    Trotter, Benjamin W.
    Dinsmore, Christopher D.
    Munshi, Nikhil C.
    Rahl, Peter B.
    Fulciniti, Mariateresa
    Lin, Charles Y.
    CANCER RESEARCH, 2024, 84 (06)
  • [48] A heterozygote point mutation in the transcription factor IRF4 protects from developing ascending paralysis in a Multiple Sclerosis mouse model
    Buckland, R.
    Pettitt, J.
    Sridharan, S.
    Roberts, N.
    Enders, A.
    Brustle, A.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 : 37 - 37
  • [49] Repression of interferon regulatory factor-4 (IRF4) hyperactivation restricts murine lupus
    Shijun He
    Huihua Ding
    Li Chen
    Yiwei Shen
    Yuting Liu
    Fenghua Zhu
    Xiaoqian Yang
    Nan Shen
    Zemin Lin
    Jianping Zuo
    Signal Transduction and Targeted Therapy, 8
  • [50] Repression of interferon regulatory factor-4 (IRF4) hyperactivation restricts murine lupus
    He, Shijun
    Ding, Huihua
    Chen, Li
    Shen, Yiwei
    Liu, Yuting
    Zhu, Fenghua
    Yang, Xiaoqian
    Shen, Nan
    Lin, Zemin
    Zuo, Jianping
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)